Additionally, the 36-month beta value for DAWN is -1.43. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for DAWN is 58.94M and currently, short sellers hold a 15.24% ratio of that float. The average trading volume of DAWN on April 12, 2024 was 627.28K shares.
DAWN) stock’s latest price update
Day One Biopharmaceuticals Inc (NASDAQ: DAWN)’s stock price has plunge by -2.43relation to previous closing price of 14.41. Nevertheless, the company has seen a -0.99% plunge in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-12-19 that BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time.
DAWN’s Market Performance
DAWN’s stock has fallen by -0.99% in the past week, with a monthly drop of -4.55% and a quarterly rise of 0.43%. The volatility ratio for the week is 5.89% while the volatility levels for the last 30 days are 5.41% for Day One Biopharmaceuticals Inc The simple moving average for the last 20 days is -5.78% for DAWN stock, with a simple moving average of 4.99% for the last 200 days.
Analysts’ Opinion of DAWN
Many brokerage firms have already submitted their reports for DAWN stocks, with BofA Securities repeating the rating for DAWN by listing it as a “Underperform.” The predicted price for DAWN in the upcoming period, according to BofA Securities is $9 based on the research report published on April 25, 2023 of the previous year 2023.
CapitalOne, on the other hand, stated in their research note that they expect to see DAWN reach a price target of $40. The rating they have provided for DAWN stocks is “Overweight” according to the report published on February 08th, 2023.
DAWN Trading at -8.04% from the 50-Day Moving Average
After a stumble in the market that brought DAWN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.23% of loss for the given period.
Volatility was left at 5.41%, however, over the last 30 days, the volatility rate increased by 5.89%, as shares sank -5.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.03% lower at present.
During the last 5 trading sessions, DAWN fell by -0.99%, which changed the moving average for the period of 200-days by +16.68% in comparison to the 20-day moving average, which settled at $14.88. In addition, Day One Biopharmaceuticals Inc saw -3.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DAWN starting from Blackman Samuel C., who sale 10,000 shares at the price of $16.01 back on Mar 25 ’24. After this action, Blackman Samuel C. now owns 1,184,662 shares of Day One Biopharmaceuticals Inc, valued at $160,055 using the latest closing price.
Blackman Samuel C., the HEAD OF R&D of Day One Biopharmaceuticals Inc, sale 30,000 shares at $15.24 during a trade that took place back on Mar 11 ’24, which means that Blackman Samuel C. is holding 1,194,662 shares at $457,314 based on the most recent closing price.
Stock Fundamentals for DAWN
Current profitability levels for the company are sitting at:
- -367.97 for the present operating margin
The net margin for Day One Biopharmaceuticals Inc stands at -324.82. The total capital return value is set at -0.59. Equity return is now at value -55.68, with -52.11 for asset returns.
Based on Day One Biopharmaceuticals Inc (DAWN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -359.93.
Currently, EBITDA for the company is -205.68 million with net debt to EBITDA at 1.06. When we switch over and look at the enterprise to sales, we see a ratio of 1782.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.72.
Conclusion
In conclusion, Day One Biopharmaceuticals Inc (DAWN) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
